AMLX:NASDAQ
Amylyx Pharmaceuticals Inc
$27.95
arrow_downward
-0.68%(-0.19) 1D
Oct 12, 10:18:05 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMLX...
Open
$28.04
High
$28.49
Low
$27.80
Mkt. cap
3.51B
Avg. vol.
1.54M
Volume
75.83K
52-wk high
$41.14
52-wk low
$10.83
EPS
-$1.43
Beta
-0.10
Shares outstanding
125.51M
No. of employees
136
Open
$28.04
High
$28.49
Low
$27.80
Mkt. cap
3.51B
Avg. vol.
1.54M
Volume
75.83K
52-wk high
$41.14
52-wk low
$10.83
EPS
-$1.43
Beta
-0.10
Shares outstanding
125.51M
No. of employees
136
News stories
From web sources and news partners
https://www.dars.gov.et/
·
1 month ago
Amylyx (AMLX) Range: Closes 2.75% Higher at $39.66 in the Latest Reading; Technical Setup
Barron's
·
1 month ago
Amylyx Stock Surges 55% After GLP-1 Blocker Hits All Trial Goals
Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
About Amylyx Pharmaceuticals Inc